<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045110</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02490</org_study_id>
    <secondary_id>NCI-2012-02490</secondary_id>
    <secondary_id>NCI-03-C-0114</secondary_id>
    <secondary_id>CDR0000256358</secondary_id>
    <secondary_id>NABTC-01-03</secondary_id>
    <secondary_id>NABTC-01-03</secondary_id>
    <secondary_id>U01CA062399</secondary_id>
    <nct_id>NCT00045110</nct_id>
    <nct_alias>NCT00055276</nct_alias>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma</brief_title>
  <official_title>A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II trial to study the effectiveness of erlotinib in treating patients who have
      recurrent malignant glioma or recurrent or progressive meningioma. Erlotinib may stop the
      growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Phase 1 I. Determine the maximum tolerated dose of erlotinib in patients with recurrent
      malignant glioma or recurrent or progressive meningioma.

      II. Determine the safety profile of this drug in these patients. III. Determine the
      pharmacokinetics of this drug in these patients.

      Phase 2 I. Determine the 6-month progression-free survival (recurrent malignant glioma)
      II.12-month survival of patients treated with this drug (stable glioblastoma post radiation
      therapy)

      Phase 2 - Secondary Recurrent Malignant Glioma I. Objective Tumor Response rate associated
      with erlotinib therapy in recurrent or progressive malignant glioma.

      III. 12-month survival of patients treated with this drug Determine the safety profile of
      this drug in these patients. IV.. Determine the pharmacokinetics of this drug in these
      patients

      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to
      study phase (I vs II), concurrent enzyme-inducing antiepileptic drugs (EIAEDs) (yes vs no),
      histology (recurrent GBM vs recurrent anaplastic glioma vs recurrent meningioma vs stable
      GBM), preoperative candidacy (yes vs no), and concurrent steroids (yes vs no).

      Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses
      repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated
      dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of
      6 patients experience dose-limiting toxicity.

      Phase II: Once the MTD is determined, additional patients concurrently receiving EIAEDs are
      treated with erlotinib as above at the phase II dose. Patients not concurrently receiving
      EIAEDs are treated with erlotinib as above at a predetermined dose.

      Patients are followed for survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I</measure>
    <time_frame>28 days</time_frame>
    <description>DLT Definition: any grade 3 thrombocytopenia and grade 4 anemia and neutropenia; any non-hematologic grade 3 toxicity; failure to recover from toxicities to be eligible for re-treatment with erlotinib within 2 weeks of the last dose of erlotinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define Maximum Tolerated Dose (MTD) of Erlotinib by Phase 1 Cohorts</measure>
    <time_frame>cycle 1 - 28 days</time_frame>
    <description>standard 3+3 dose escalation design 3 patients in each dose level, observed for 28 days before enrollment to next level. if none of the patients experienced DLT dose escalated, if 1 of 3 experienced DLT 3 more enrolled at that level, if none of the 3 additional pts had DLT escalate to next level, if one or more of the additional pts experienced DLT, the MTD was exceeded and 3 more patients were treated at the next lower dose (if only 3 pts treated at the lower dose). The MTD is the dose at which 0/3 or 1/6 patients have experienced a DLT with the next higher dose having at least 2/3 or 2/6 patients encountering DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Months Progression-free Survival in Recurrent Malignant Gliomas (Phase II)</measure>
    <time_frame>6 months</time_frame>
    <description>Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a Grade 3 or 4 Adverse Events Phase 1</measure>
    <time_frame>1 year</time_frame>
    <description>CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Survival - Phase II Newly Diagnosed GBM Post RT</measure>
    <time_frame>At 1 year</time_frame>
    <description>12 month survival for newly diagnosed stable GBM post RT treated with erlotinib post RT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Newly Diagnosed GBM Post RT</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival defined as Time from Start of treatment to time of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Complete or Partial Response) Graded Using Modified RECIST Criteria Phase II</measure>
    <time_frame>At 1 year</time_frame>
    <description>Measurable: Bidimensionally measurable lesions w/ clearly defined margins by MRI
Evaluable: Unidimensionally measurable lesions, masses w/margins not clearly defined.
Complete Response (CR): Complete disappearance of all measurable/evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients on minimal/no steroids.
Partial Response (PR): &gt;/= to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. Responders must be on same/decreasing doses of dexamethasone.
Stable/No Response: Does not qualify for CR, PR, or progression.
Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With One or More Grade 3-5 Toxicity Described Based on the CTC Severity Grading Phase II</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summarized by descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -</measure>
    <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1.</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -</measure>
    <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the Area Under the Curve Per Dose Level Phase I (on Anticonvulsants) -</measure>
    <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Level Per Dose Level Phase I (on Anticonvulsants) -</measure>
    <time_frame>cycle 1 day eight</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</measure>
    <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Plasma Concentration for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</measure>
    <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of Area Under the Curve for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg-</measure>
    <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</measure>
    <time_frame>One sample on day 8 cycle 1</time_frame>
    <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs</measure>
    <time_frame>Pre-surgery and time of resection</time_frame>
    <description>Drug administered 6 days prior to surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tissue) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs</measure>
    <time_frame>Pre-surgery and time of resection</time_frame>
    <description>Drug administered 6 days prior to surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Grade I Meningioma</condition>
  <condition>Adult Grade II Meningioma</condition>
  <condition>Adult Grade III Meningioma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
erlotinib hydrochloride given orally
Other: pharmacological study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 recurrent malignant gliomas and nonprogressive GBM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose (150mg/day.
patients requiring surgery treated 7 days prior to tumor removal (150mg/day)
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>given orally</description>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 recurrent malignant gliomas and nonprogressive GBM</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>correlative studies</description>
    <arm_group_label>Phase 2 recurrent malignant gliomas and nonprogressive GBM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>correlative studies</description>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 recurrent malignant gliomas and nonprogressive GBM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One of the following diagnoses:

               -  Histologically confirmed intracranial malignant glioma

                    -  Glioblastoma multiforme (GBM), anaplastic astrocytoma, anaplastic
                       oligodendroglioma, anaplastic mixed oligoastrocytoma, or malignant
                       astrocytoma not otherwise specified

                    -  Original histology of low-grade glioma allowed provided a subsequent
                       histology of malignant glioma is confirmed

               -  Histologically or radiographically confirmed recurrent or progressive benign or
                  malignant meningioma

          -  Progressive disease or tumor recurrence on MRI or CT scan

               -  Phase I: No more than 3 prior relapses and no more than 2 prior chemotherapy* or
                  biologic therapy regimens

               -  Phase II: No more than 2 prior relapses and no more than 2 prior chemotherapy* or
                  biologic therapy regimens

          -  Patients with progressive disease must have failed prior radiotherapy* that was
             completed at least 4 weeks ago

               -  Patients with progressive disease between 4 and 12 weeks after completion of
                  external beam radiotherapy must have clear evidence of progression on MRI

               -  Patients with GBM who have completed external beam radiotherapy and do not show
                  progression are eligible

               -  Patients with progressive disease after interstitial brachytherapy or
                  stereotactic radiosurgery must have confirmed true progression rather than
                  radiation necrosis based upon positron-emission tomography, thallium scanning,
                  MRI, or surgical documentation

          -  Measurable or evaluable disease

          -  Performance status - Karnofsky 60-100%

          -  More than 8 weeks

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 mg/dL (transfusion allowed)

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  SGOT less than 1.5 times ULN

          -  Creatinine less than 1.5 mg/dL

          -  None of the following ophthalmic abnormalities:

               -  Abnormalities of the cornea (e.g., dry eye syndrome or Sj√∂gren's syndrome)

               -  Congenital abnormality (e.g., Fuch's dystrophy)

               -  Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or
                  Bengal-Rose)

               -  Abnormal corneal sensitivity test (Schirmer test or similar tear production test)

          -  Patients found to have dry eyes on examination but have an otherwise normal
             examination allowed

          -  No active infection

          -  No other serious concurrent medical illness

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No other disease that would obscure toxicity or dangerously alter drug metabolism

          -  No significant medical illness that would preclude study participation

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 12 weeks
             after study participation

          -  See Disease Characteristics

          -  At least 1 week since prior thalidomide

          -  At least 1 week since prior interferon

          -  At least 4 weeks since prior SU5416 or other experimental biologic agents

          -  See Disease Characteristics

          -  No prior chemotherapy (including polifeprosan 20 with carmustine implant [Gliadel
             wafers]) for patients with stable GBM

          -  At least 2 weeks since prior vincristine

          -  At least 3 weeks since prior procarbazine

          -  At least 6 weeks since prior nitrosoureas

          -  At least 1 week since prior tamoxifen

          -  See Disease Characteristics

          -  Recovered from prior radiotherapy

          -  No more than 6 weeks since prior external beam radiotherapy for patients with GBM
             without evidence of progression

          -  Recovered from prior surgery

          -  Recovered from prior therapy

          -  At least 1 week since prior noncytotoxic agents (e.g., isotretinoin) except
             radiosensitizers

          -  At least 4 weeks since prior cytotoxic therapy

          -  At least 4 weeks since prior tipifarnib or imatinib mesylate

          -  No prior erlotinib or other epidermal growth factor receptor inhibitors

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Abrey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute Neuro-Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010 Jan;12(1):87-94. doi: 10.1093/neuonc/nop017. Epub 2009 Dec 14.</citation>
    <PMID>20150371</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>May 4, 2017</results_first_submitted>
  <results_first_submitted_qc>June 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrolled between August 15, 2002 and August 18, 2005. Patient recruited from outpatient oncology centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1 Dose Escalation</title>
          <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.</description>
        </group>
        <group group_id="P2">
          <title>Phase 2 - Recurrent Malignant Glioma</title>
          <description>Phase II: Once the MTD is determined, additional patients concurrently receiving EIAEDs are treated with erlotinib as above at the phase II dose.
Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal; PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.</description>
        </group>
        <group group_id="P3">
          <title>Phase 2 - Newly Diagnosed GBM Post RT</title>
          <description>Patients with GBM with newly diagnosed disease following Radiation (RT) started erlotinib no more than 6 weeks from the completion of RT. Temozolomide or other adjuvant chemotherapy not allowed while on erotinib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>100mg Phase 1 Dose Escalalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not initiate treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>prior treatment history</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible histology</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>200mg Phase 1 Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>275mg Phase 1 Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>400mg Phase 1 Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>525mg Phase 1 Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>650mg Phase 1 Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>775mg Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>enrolled between 8/2002 and 8/2005. All recruited from outpatient setting.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1 Dose Escalation</title>
          <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.</description>
        </group>
        <group group_id="B2">
          <title>Phase 2 w/ Recurrent Malignant Glioma</title>
          <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib at a predetermined dose (150mg/day).
Patients requiring surgery were treated 7 days prior to tumor removal PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR) erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis</description>
        </group>
        <group group_id="B3">
          <title>Phase 2 Newly Diagnosed GBM Post RT</title>
          <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose. (150mg/day)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="19" upper_limit="76"/>
                    <measurement group_id="B2" value="54" lower_limit="29" upper_limit="78"/>
                    <measurement group_id="B3" value="52" lower_limit="19" upper_limit="72"/>
                    <measurement group_id="B4" value="52" lower_limit="19" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Glioblastoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaplastic Astrocytoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaplastic oligodendroglioma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atypical meningioma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleomorphic Xanthoastrocytoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oligodendroglioma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Radiation Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Number of Chemotherapy Regimens</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status Scale</title>
          <description>Higher score better 100 normal no complaints/disease 90 capable normal activity few symptoms/disease 80 normal activity, some difficulty some symptoms/signs 70 caring for self not capable normal activity/work 60 requiring some help can take care of most personal requirements 50 requires help often requires frequent medical care 40 disabled requires special care/help 30 severely disabled hospital admission indicated but no risk of death 20 very ill urgently requiring admission requires supportive measures/treatment 10 moribund rapidly progressive fatal disease processes 0 death</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B2" value="80" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B3" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B4" value="80" lower_limit="60" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I</title>
        <description>DLT Definition: any grade 3 thrombocytopenia and grade 4 anemia and neutropenia; any non-hematologic grade 3 toxicity; failure to recover from toxicities to be eligible for re-treatment with erlotinib within 2 weeks of the last dose of erlotinib.</description>
        <time_frame>28 days</time_frame>
        <population>Patients were eligible if they had recurrent disease or if they were newly diagnosed post RT and did NOT have tumor progression (nonprogression glioblastoma) on Enzyme-inducing Antiepileptic Drugs</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation</title>
            <description>Phase I: Patients concurrently receiving EIAEDs ( on Enzyme-inducing Antiepileptic Drugs ) receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Other: pharmacological study, laboratory biomarker analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I</title>
          <description>DLT Definition: any grade 3 thrombocytopenia and grade 4 anemia and neutropenia; any non-hematologic grade 3 toxicity; failure to recover from toxicities to be eligible for re-treatment with erlotinib within 2 weeks of the last dose of erlotinib.</description>
          <population>Patients were eligible if they had recurrent disease or if they were newly diagnosed post RT and did NOT have tumor progression (nonprogression glioblastoma) on Enzyme-inducing Antiepileptic Drugs</population>
          <units>dose limiting toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 150mg (Rash)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 200mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 275mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 400mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 525mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 650mg (DVT/PE)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 775mg (Rash [2])</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Define Maximum Tolerated Dose (MTD) of Erlotinib by Phase 1 Cohorts</title>
        <description>standard 3+3 dose escalation design 3 patients in each dose level, observed for 28 days before enrollment to next level. if none of the patients experienced DLT dose escalated, if 1 of 3 experienced DLT 3 more enrolled at that level, if none of the 3 additional pts had DLT escalate to next level, if one or more of the additional pts experienced DLT, the MTD was exceeded and 3 more patients were treated at the next lower dose (if only 3 pts treated at the lower dose). The MTD is the dose at which 0/3 or 1/6 patients have experienced a DLT with the next higher dose having at least 2/3 or 2/6 patients encountering DLT.</description>
        <time_frame>cycle 1 - 28 days</time_frame>
        <population>Cohorts/dose levels: 150mg; 200mg; 275mg; 400mg; 525mg; 650mg; 775mg patients on Enzyme-inducing Antiepileptic Drugs</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation</title>
            <description>Phase I: Patients concurrently receiving EIAEDs ( on Enzyme-inducing Antiepileptic Drugs) receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Other: pharmacological study, laboratory biomarker analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Define Maximum Tolerated Dose (MTD) of Erlotinib by Phase 1 Cohorts</title>
          <description>standard 3+3 dose escalation design 3 patients in each dose level, observed for 28 days before enrollment to next level. if none of the patients experienced DLT dose escalated, if 1 of 3 experienced DLT 3 more enrolled at that level, if none of the 3 additional pts had DLT escalate to next level, if one or more of the additional pts experienced DLT, the MTD was exceeded and 3 more patients were treated at the next lower dose (if only 3 pts treated at the lower dose). The MTD is the dose at which 0/3 or 1/6 patients have experienced a DLT with the next higher dose having at least 2/3 or 2/6 patients encountering DLT.</description>
          <population>Cohorts/dose levels: 150mg; 200mg; 275mg; 400mg; 525mg; 650mg; 775mg patients on Enzyme-inducing Antiepileptic Drugs</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Months Progression-free Survival in Recurrent Malignant Gliomas (Phase II)</title>
        <description>Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>6 months</time_frame>
        <population>38 Glioblastoma, 15 anaplastic gliomas not receiving Enzyme-inducing Antiepileptic Drugs</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Recurrent Malignant Gliomas</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>6 Months Progression-free Survival in Recurrent Malignant Gliomas (Phase II)</title>
          <description>Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <population>38 Glioblastoma, 15 anaplastic gliomas not receiving Enzyme-inducing Antiepileptic Drugs</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recurrent GBM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent Anaplastic Glioma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a Grade 3 or 4 Adverse Events Phase 1</title>
        <description>CTCAE</description>
        <time_frame>1 year</time_frame>
        <population>During Cycle 1 only grade 3 severity; patients on Enzyme-inducing Antiepileptic Drugs</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation</title>
            <description>Phase I: Patients concurrently receiving EIAEDs (on Enzyme-inducing Antiepileptic Drugs) receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Other: pharmacological study, laboratory biomarker analysis..
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Grade 3 or 4 Adverse Events Phase 1</title>
          <description>CTCAE</description>
          <population>During Cycle 1 only grade 3 severity; patients on Enzyme-inducing Antiepileptic Drugs</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Year Survival - Phase II Newly Diagnosed GBM Post RT</title>
        <description>12 month survival for newly diagnosed stable GBM post RT treated with erlotinib post RT</description>
        <time_frame>At 1 year</time_frame>
        <population>not receiving Enzyme-inducing Antiepileptic Drugs; stable glioblastoma after RT</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Newly Diagnosed GBM Post RT</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose. (150mg/day)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis</description>
          </group>
        </group_list>
        <measure>
          <title>1 Year Survival - Phase II Newly Diagnosed GBM Post RT</title>
          <description>12 month survival for newly diagnosed stable GBM post RT treated with erlotinib post RT</description>
          <population>not receiving Enzyme-inducing Antiepileptic Drugs; stable glioblastoma after RT</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Newly Diagnosed GBM Post RT</title>
        <description>Overall Survival defined as Time from Start of treatment to time of death due to any cause</description>
        <time_frame>2 years</time_frame>
        <population>not receiving Enzyme-inducing Antiepileptic Drugs, glioblastoma stable after RT</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Newly Diagnosed GBM Post RT</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose. (150mg/day)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Newly Diagnosed GBM Post RT</title>
          <description>Overall Survival defined as Time from Start of treatment to time of death due to any cause</description>
          <population>not receiving Enzyme-inducing Antiepileptic Drugs, glioblastoma stable after RT</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (Complete or Partial Response) Graded Using Modified RECIST Criteria Phase II</title>
        <description>Measurable: Bidimensionally measurable lesions w/ clearly defined margins by MRI
Evaluable: Unidimensionally measurable lesions, masses w/margins not clearly defined.
Complete Response (CR): Complete disappearance of all measurable/evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients on minimal/no steroids.
Partial Response (PR): &gt;/= to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. Responders must be on same/decreasing doses of dexamethasone.
Stable/No Response: Does not qualify for CR, PR, or progression.
Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>At 1 year</time_frame>
        <population>recurrent malignant gliomas - anaplastic and glioblastoma</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Recurrent Malignant Gliomas</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete or Partial Response) Graded Using Modified RECIST Criteria Phase II</title>
          <description>Measurable: Bidimensionally measurable lesions w/ clearly defined margins by MRI
Evaluable: Unidimensionally measurable lesions, masses w/margins not clearly defined.
Complete Response (CR): Complete disappearance of all measurable/evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients on minimal/no steroids.
Partial Response (PR): &gt;/= to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. Responders must be on same/decreasing doses of dexamethasone.
Stable/No Response: Does not qualify for CR, PR, or progression.
Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over BL if no decrease), OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <population>recurrent malignant gliomas - anaplastic and glioblastoma</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With One or More Grade 3-5 Toxicity Described Based on the CTC Severity Grading Phase II</title>
        <description>Summarized by descriptive statistics.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>drug related events grade 3-5 CTCAE. 5 patients were not evaluable for response/toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Recurrent Malignant Gliomas and Stable Disease Post RT</title>
            <description>Patients with recurrent malignant gliomas not concurrently receiving EIAEDs treated with erlotinib at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With One or More Grade 3-5 Toxicity Described Based on the CTC Severity Grading Phase II</title>
          <description>Summarized by descriptive statistics.</description>
          <population>drug related events grade 3-5 CTCAE. 5 patients were not evaluable for response/toxicity.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1.</time_frame>
        <population>tmax=time of peak plasma concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation - 150 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Other: pharmacological study, laboratory biomarker analysis.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation - 200 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation - 275 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation - 400 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation - 525 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation - 650 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation - 775 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>tmax=time of peak plasma concentration</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.37"/>
                    <measurement group_id="O2" value="2.8" spread="2.2"/>
                    <measurement group_id="O3" value="3.3" spread="1.2"/>
                    <measurement group_id="O4" value="6" spread="0"/>
                    <measurement group_id="O5" value="3.5" spread="3.54"/>
                    <measurement group_id="O6" value="2.2" spread="0.98"/>
                    <measurement group_id="O7" value="2.4" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
        <population>Cp=peak plasma concentration;</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation - 150 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Other: pharmacological study, laboratory biomarker analysis.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation - 200 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation - 275 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation - 400 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation - 525 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation - 650 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation - 775 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>Cp=peak plasma concentration;</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603" spread="160"/>
                    <measurement group_id="O2" value="722" spread="186"/>
                    <measurement group_id="O3" value="1075" spread="308"/>
                    <measurement group_id="O4" value="487" spread="0"/>
                    <measurement group_id="O5" value="2327" spread="1609"/>
                    <measurement group_id="O6" value="1351" spread="441"/>
                    <measurement group_id="O7" value="2009" spread="1133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimation of the Area Under the Curve Per Dose Level Phase I (on Anticonvulsants) -</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
        <population>AUC=area under the curve</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation - 150 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Other: pharmacological study, laboratory biomarker analysis.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation - 200 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation - 275 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation - 400 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation - 525 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation - 650 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation - 775 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of the Area Under the Curve Per Dose Level Phase I (on Anticonvulsants) -</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>AUC=area under the curve</population>
          <units>ug* h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="2.04"/>
                    <measurement group_id="O2" value="7.28" spread="2.54"/>
                    <measurement group_id="O3" value="13.58" spread="2.99"/>
                    <measurement group_id="O4" value="21.09" spread="0"/>
                    <measurement group_id="O5" value="25.94" spread="21.6"/>
                    <measurement group_id="O6" value="15.77" spread="7.43"/>
                    <measurement group_id="O7" value="18.83" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Level Per Dose Level Phase I (on Anticonvulsants) -</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>cycle 1 day eight</time_frame>
        <population>trough level</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Dose Escalation - 150 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Other: pharmacological study, laboratory biomarker analysis.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Escalation - 200 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Dose Escalation - 275 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Dose Escalation - 400 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1 Dose Escalation - 525 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1 Dose Escalation - 650 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
          <group group_id="O7">
            <title>Phase 1 Dose Escalation - 775 mg</title>
            <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.
The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Level Per Dose Level Phase I (on Anticonvulsants) -</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>trough level</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412" spread="430"/>
                    <measurement group_id="O2" value="227" spread="82"/>
                    <measurement group_id="O3" value="821" spread="154"/>
                    <measurement group_id="O4" value="634" spread="0"/>
                    <measurement group_id="O5" value="1356" spread="132"/>
                    <measurement group_id="O6" value="591" spread="574"/>
                    <measurement group_id="O7" value="942" spread="775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
        <population>Cpmax =peak plasma concentration;</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Recurrent Malignant Gliomas</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>Cpmax =peak plasma concentration;</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872" spread="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Plasma Concentration for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
        <population>tmax=time to peak plasma concentration;</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Recurrent Malignant Gliomas</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Plasma Concentration for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>tmax=time to peak plasma concentration;</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimation of Area Under the Curve for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg-</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>baseline, 1,2,4,6,8,12,24h post administration day 1 cycle 1. One sample on day 8 cycle 1 and day 1 of cycle 2,3 and 5</time_frame>
        <population>AUC=area under the curve;</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Recurrent Malignant Gliomas</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of Area Under the Curve for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg-</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>AUC=area under the curve;</population>
          <units>ug * h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.86" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</title>
        <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
        <time_frame>One sample on day 8 cycle 1</time_frame>
        <population>Cp=peak plasma concentration; tmax=time to Cp; AUC=area under the curve;</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Recurrent Malignant Gliomas</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal
PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.
erlotinib hydrochloride: given orally
laboratory biomarker analysis: correlative studies
pharmacological study: correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -</title>
          <description>plasma concentrations relative to erlotiniab administration and sample time and dose level</description>
          <population>Cp=peak plasma concentration; tmax=time to Cp; AUC=area under the curve;</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="975" spread="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Plasma) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs</title>
        <description>Drug administered 6 days prior to surgery</description>
        <time_frame>Pre-surgery and time of resection</time_frame>
        <population>sample 5 and 6 suspected of contamination with blood clot</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Newly Diagnosed GBM Post RT</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose. (150mg/day)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Plasma) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs</title>
          <description>Drug administered 6 days prior to surgery</description>
          <population>sample 5 and 6 suspected of contamination with blood clot</population>
          <units>plasma concentration ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761" spread="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Tissue) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs</title>
        <description>Drug administered 6 days prior to surgery</description>
        <time_frame>Pre-surgery and time of resection</time_frame>
        <population>sample 5 and 6 suspected of contamination with blood clot tumor/tissue concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Newly Diagnosed GBM Post RT</title>
            <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose. (150mg/day)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Tissue) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs</title>
          <description>Drug administered 6 days prior to surgery</description>
          <population>sample 5 and 6 suspected of contamination with blood clot tumor/tissue concentration</population>
          <units>tumor/tissue concentration ng/g dry weig</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497" spread="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 1 Dose Escalation</title>
          <description>Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.</description>
        </group>
        <group group_id="E2">
          <title>Phase 2 Recurrent Malignant Gliomas and Nonprogressive Gbm</title>
          <description>Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.
patients requiring surgery were treated 7 days prior to tumor removal; PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
erlotinib hydrochloride given orally
Other: pharmacological study, laboratory biomarker analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>granulocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="32"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lauren E Abrey, MD</name_or_title>
      <organization>Adult Brain Tumor Consortium</organization>
      <phone>410-955-8837</phone>
      <email>jfisher@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

